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Antibody guided lymphangiography in the staging of
cervical cancer
A.A. Epenetos
Jor the 'Hammersmith Oncology Group (HOG) and the 2Imperial Cancer Research Fund (ICRF).
Summary Iodine-123-labelled tumour associated monoclonal antibody HMFG2 was administered
intralymphatically at a time that cannulation of pedal lymphatic vessels was performed for standard
lymphangiography in 6 patients with cervical cancer. Gamma camera images were taken at 2h and 24h after
injection of antibody and at a similar time that X-ray lymphangiography was performed.
Five out of the 6 standard lymphangiograms were reported as normal whilst one showed definite evidence
of metastasis. Antibody guided analysis of the abnormal lymphangiogram confirmed the presence of
abnormality. Also, marked non-specific uptake of antibody was seen on all lymphangiograms. It is concluded
that, in order for monoclonal antibody guided lymphangiography to become a useful adjunct to standard
lymphangiography, further improvements are needed to reduce non-specific uptake by normal lymphatics.
Bilateral pedal lymphangiography is an important
staging procedure for carcinoma of the cervix
(Halnan, 1982). The presence and extent of
lymphatic involvement can determine the form of
therapy and help in the planning of radiotherapy.
Unfortunately, approximately 20% of lymphangio-
grams (Piver et al., 1971) are reported as equivocal
and more invasive techniques such as needle
aspiration of suspicious lymph nodes are required
in order to reach a cytological diagnosis; of course,
lymph node aspiration can only provide definitive
information on the individual aspirated lymph nodes.
Therefore, less invasive and more comprehensive
techniques are needed to enhance the diagnostic
accuracy of standard lymphangiography.
Radiolabelled tumour associated monoclonal
antibodies are increasingly being used for the radio-
immunolocalisation of primary and metastatic
malignant disease and encouraging results have
been reported (Mach et al., 1981; Epenetos et al.,
1982). Unfortunately, imaging using intravenously
administered radiolabelled antibodies is limited by
background radioactivity in the blood pool and
extravascular spaces and, furthermore, antibodies
may be catabolised and removed before reaching
their target resulting in only a very small tumour
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uptake. Also, dehalogenation of radiolabelled anti-
bodies (Sullivan et al., 1982) and hepatic uptake
(Rainsbury et al., 1983) of Indium-III labelled
antibodies are further limitations to successful
antibody targeting.
It is possible that lymphatic delivery of antibody
may be more efficient than intravenous adminis-
tration in the imaging of lymphatic deposits. Some
animal studies support this by showing that sub-
cutaneous injection of an antibody can locate
metastases in the draining lymph node (Weinstein
et al., 1983). Subcutaneous injection of antibody is,
however, un "uncontrolled" form of administration
of radioactive tracers and therefore we chose to
study the lymphatic route by taking advantage of
the cannulation of pedal lymphatic vessels during
standard lymphangiography. Antibody HMFG2
was selected because in previous immunoperoxidase
studies (Epenetos, 1983) it reacted positively against
all (8 out of 8) cervical carcinomas and not against
any lymphoid tissues.
Patients and methods
Patients
Six women aged 25-75 with the diagnosis of
cervical carcinoma gave their written informed
consent and were skin tested for mouse immuno-
globulin allergy prior to entering the study. They
were given potassium iodide 120mgday-1 for 7
days.
Monoclonal antibodies
HMFG2 This mouse IgGl (Arklie et al., 1981)
reacts positively with a wide rage of carcinomas,
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including those of cervix. It does not react with
normal lymph nodes.
UJ13A This mouse IgGl (Kempshead et al., 1983)
is a neuroblastoma associated antibody and does
not react against cervical cancer or normal lymph
nodes. It was used as a negative control.
Radiolabelling ofantibodies
Pure Iodine-123 (the Atomic Energy Research
Establishment, Harwell) was used for labelling
HMFG2, and Iodine-131 (Amersham International,
Amersham) was used for labelling UJ13A.
Antibodies were iodinated using the iodogen
technique (Epenetos et al., 1982). Antibody re-
activity was tested in an enzyme linked immuno-
sorbent assay (ELISA) (Epenetos et al., 1982)
and in a direct radioimmunoassay (RIA) including
a competitive assay with unlabelled antibodies.
Samples of radiolabelled antibodies were gel filtered
through a Sephadex GI50 column (60cm x 2.5cm)
to test for antibody aggregates. They were millipore
filtered and diluted in 1% human serum albumin
(HSA) prior to patient administration.
Lymphangiography
Conventional bipedal lymphangiography was
performed uneventfully in the 6 patients with
cervical carcinoma. One mCi HMFG2 labelled with
1231 was injected over a 5min period in each foot,
followed by 5ml normal saline and lipiodol
infusion over 30-60min in the conventional
fashion. When negative control antibody UJ13A
was used, 0.5mCi 1311-labelled protein was given
simultaneously with 123I-labelled HMFG2.
Antibody guided scanning
Anterior scans of legs, pelvis and abdomen were
taken at 2h and 24h after antibody injection using
a gamma camera (GE) fitted with a high sensitivity
collimator. When 131I-labelled antibody was given
simultaneously with 123I-labelled antibody, a high
energy collimator was used for imaging both
isotopes.
Results
Antibodies were satisfactorily labelled with 1231 and
131I to a specific activity of 3-8pCimg-. There
was no loss of immunoreactivity, as illustrated in
Figure 1 and no aggregate formation following
iodinations. There were no allergies to the
administered antibodies.
Five out of 6 standard lymphangiograms were
reported as normal and one was markedly
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Figure 1 Direct radioimmunoassay of 123I-labelled
monoclonal antibody HMFG2. (0) indicates the
binding of 123I HMFG2 on target cells (T47D 5 x 104
cells per well) whilst (El) shows the binding of 123I
HMFG2 in competition with 2jig of unlabelled
HMFG2 added to each dilution of 123I HMFG2.
(Starting amounts of 123I HMFG2 were 2,ug and
7.5 x 10 cpm). As can be seen, 123J HMFG2 competes
well with unlabelled HMFG2 for antigen binding. (A)
indicates the negligible binding of a negative control
monoclonal antibody 123I H17E2 (starting amounts
2,ug and 7.5 x 105cpm).
abnormal with evidence of lymph node metastases
(Figure 2). Anterior antibody guided scans were
taken with 350,000 counts per image. Scans of all
6 patients showed marked non-specific antibody
uptake by normal lymph nodes and lymphatic
vessels. This was noted for both specific and non-
specific antibodies (Figure 3a and 3b respectively)
and it persisted for the full period of observations
(i.e. up to 34h after injection).
The antibody guided scan of the abnormal
lymphangiograms showed abnormal antibody
distribution in both iliac regions both sides of the
pelvis and also a possible area of uptake in the left
para-aortic region (Figure 4). These abnormalities
were noted only in the 24h scan.
Pelvic examination under anaesthesia showed
parameterial involvement to the pelvic side wall on
both sides, confirming the findings of antibody
guided lymphangiography.
Discussion
This study demonstrates that an Iodine-123-labelled
tumour associated monoclonal antibody HMFG2
can be simply and safely administered intra-ANTIBODY-GUIDED LYMPHANGIOGRAPHY IN CERVICAL CANCER
Figure 2 Standard lymphangiogram showing bi-
laterally abnormal iliac lymph nodes due to metastatic
involvement.
Figure 3(a) Antibody guided lymphangiography of a
patient without evidence of disease using specific
antibody HMFG2 labelled with 1231. Note non-specific
uptake in inguinal and iliac regions. This was seen
both in the early (2h) and late (24h) scans.
3(b) Antibody guided lymphangiography of the same
patient as in Figure 3a using non-specific antibody
UJ13A labelled with 131I. Note non-specific uptake in
inguinal and iliac regions in a similar fashion to Figure
3a. It must be noted that Figure 3b is a true image of
the 13I counts while Figure 3a contains both 1231
counts as well as -20% counts due to overlap arising
from the higher energy of 131i.
__
Figure 4 Antibody guided scan of the abnormal
lymphangiogram shown in Figure 2. There is evidence
of abnormal uptake involving both sides of the pelvis.
This was observed in the 24h scan but not in the 2h
scan. Such abnormalities were not seen in the other 5
patients whohadnormalconventionallymphangiograms.
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lymphatically during standard lymphangiography
in the staging of cervical cancer. A problem that
has been identified in this study is that of marked
non-specific uptake of antibody by normal lymph
nodes and lymphatic channels. This phenomenon is
clearly demonstrated in the case where both specific
and non-specific antibodies labelled with 1231 and
1311 respectively produced almost identical images
of lymphatics. This is probably due to binding
through the Fc portion of the mouse immuno-
globulin and therefore the use of antibody
fragments rather than whole immunoglobulin
should reduce non-specific uptake and improve
images.
Nevertheless, it was encouraging to note that the
one abnormal lymphangiogram also showed an
abnormal image on antibody guided scanning
suggesting that some antibody is reaching its target
despite significant non-specific uptake by normal
lymphatics. A limitation of lymphatic delivery is of
course the restriction of antibody to the lymphatic
chain that has been injected into but lymphatic
status is an important staging procedure in several
malignant diseases, including carcinoma of the
cervix.
We are grateful to Dr W.F. Bodmer, Imperial Cancer
Research Fund, for his constructive comments, and to
Miss Ann Freemantle for typing this manuscript.
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